Oxaliplatin Microdosing Assay in Predicting Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy
Status:
Completed
Trial end date:
2020-04-04
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies how well carbon C 14 oxaliplatin microdosing assay works in
predicting exposure and sensitivity to oxaliplatin-based chemotherapy in patients with
colorectal cancer that has spread to other places in the body and usually cannot be cured or
controlled with treatment. Drugs used in chemotherapy, such as oxaliplatin, work in different
ways to stop the growth of tumor cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Carbon C 14 is a radioactive form of carbon,
exists in nature and in the body at a low level. Microdose carbon C 14 oxaliplatin diagnostic
assay may help doctors understand how well patients respond to treatment and develop
individualize oxaliplatin dosing in patients with colorectal cancer.